216 related articles for article (PubMed ID: 27766347)
21. Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose.
Erus G; Battapady H; Zhang T; Lovato J; Miller ME; Williamson JD; Launer LJ; Bryan RN; Davatzikos C
Diabetes Care; 2015 Jan; 38(1):97-104. PubMed ID: 25336747
[TBL] [Abstract][Full Text] [Related]
22. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.
Griffin SJ; Bethel MA; Holman RR; Khunti K; Wareham N; Brierley G; Davies M; Dymond A; Eichenberger R; Evans P; Gray A; Greaves C; Harrington K; Hitman G; Irving G; Lessels S; Millward A; Petrie JR; Rutter M; Sampson M; Sattar N; Sharp S
Health Technol Assess; 2018 Apr; 22(18):1-64. PubMed ID: 29652246
[TBL] [Abstract][Full Text] [Related]
23. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
24. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
25. A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment.
Nauck MA; Haastert B; Trautner C; Müller UA; Nauck MA; Heinemann L;
Diabetologia; 2014 May; 57(5):868-77. PubMed ID: 24445534
[TBL] [Abstract][Full Text] [Related]
26. Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus.
Freedman BI; Sink KM; Hugenschmidt CE; Hughes TM; Williamson JD; Whitlow CT; Palmer ND; Miller ME; Lovato LC; Xu J; Smith SC; Launer LJ; Barzilay JI; Cohen RM; Sullivan MD; Bryan RN; Wagner BC; Bowden DW; Maldjian JA; Divers J;
Am J Kidney Dis; 2017 Nov; 70(5):627-637. PubMed ID: 28648301
[TBL] [Abstract][Full Text] [Related]
27. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.
Seaquist ER; Miller ME; Fonseca V; Ismail-Beigi F; Launer LJ; Punthakee Z; Sood A
J Diabetes Complications; 2013; 27(5):485-91. PubMed ID: 23680059
[TBL] [Abstract][Full Text] [Related]
28. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial.
Nasrallah IM; Gaussoin SA; Pomponio R; Dolui S; Erus G; Wright CB; Launer LJ; Detre JA; Wolk DA; Davatzikos C; Williamson JD; Pajewski NM; Bryan RN;
JAMA Neurol; 2021 May; 78(5):568-577. PubMed ID: 33683313
[TBL] [Abstract][Full Text] [Related]
29. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Beulens JW; Patel A; Vingerling JR; Cruickshank JK; Hughes AD; Stanton A; Lu J; McG Thom SA; Grobbee DE; Stolk RP; ;
Diabetologia; 2009 Oct; 52(10):2027-36. PubMed ID: 19633827
[TBL] [Abstract][Full Text] [Related]
30. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.
ACCORD Study Group
Diabetes Care; 2016 May; 39(5):701-8. PubMed ID: 26822326
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
33. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Biessels GJ; Verhagen C; Janssen J; van den Berg E; Wallenstein G; Zinman B; Espeland MA; Johansen OE
Diabetologia; 2021 Jun; 64(6):1235-1245. PubMed ID: 33559704
[TBL] [Abstract][Full Text] [Related]
34. A clinical and economic evaluation of Control of Hyperglycaemia in Paediatric intensive care (CHiP): a randomised controlled trial.
Macrae D; Grieve R; Allen E; Sadique Z; Betts H; Morris K; Pappachan VJ; Parslow R; Tasker RC; Baines P; Broadhead M; Duthie ML; Fortune PM; Inwald D; McMaster P; Peters MJ; Schindler M; Guerriero C; Piercy D; Slavik Z; Snowdon C; Van Dyck L; Elbourne D
Health Technol Assess; 2014 Apr; 18(26):1-210. PubMed ID: 24780450
[TBL] [Abstract][Full Text] [Related]
35. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial.
Nilsson M; Jensen N; Gejl M; Bergmann ML; Storgaard H; Zander M; Miskowiak K; Rungby J
Diabetologia; 2019 Oct; 62(10):1948-1958. PubMed ID: 31367958
[TBL] [Abstract][Full Text] [Related]
36. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.
Taheri S; Zaghloul H; Chagoury O; Elhadad S; Ahmed SH; El Khatib N; Amona RA; El Nahas K; Suleiman N; Alnaama A; Al-Hamaq A; Charlson M; Wells MT; Al-Abdulla S; Abou-Samra AB
Lancet Diabetes Endocrinol; 2020 Jun; 8(6):477-489. PubMed ID: 32445735
[TBL] [Abstract][Full Text] [Related]
37. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.
Rapp SR; Gaussoin SA; Sachs BC; Chelune G; Supiano MA; Lerner AJ; Wadley VG; Wilson VM; Fine LJ; Whittle JC; Auchus AP; Beddhu S; Berlowitz DR; Bress AP; Johnson KC; Krousel-Wood M; Martindale-Adams J; Miller EC; Rifkin DE; Snyder JK; Tamariz L; Wolfgram DF; Cleveland ML; Yang M; Nichols LO; Bryan RN; Reboussin DM; Williamson JD; Pajewski NM;
Lancet Neurol; 2020 Nov; 19(11):899-907. PubMed ID: 33098800
[TBL] [Abstract][Full Text] [Related]
38. Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.
van den Burg EL; Schoonakker MP; van Peet PG; van den Akker-van Marle EM; Lamb HJ; Longo VD; Numans ME; Pijl H
Diabetologia; 2024 Jul; 67(7):1245-1259. PubMed ID: 38546821
[TBL] [Abstract][Full Text] [Related]
39. Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus.
Gupta A; Boucher R; Wei G; Gronseth G; Parks A; Beddhu S
Am J Hypertens; 2023 Feb; 36(2):120-125. PubMed ID: 36227718
[TBL] [Abstract][Full Text] [Related]
40. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
Punthakee Z; Miller ME; Simmons DL; Riddle MC; Ismail-Beigi F; Brillon DJ; Bergenstal RM; Savage PJ; Hramiak I; Largay JF; Sood A; Gerstein HC;
Diabetologia; 2014 Oct; 57(10):2030-7. PubMed ID: 24985147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
